Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | LCAT | P04180 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249116 | 0.92 | ABL1 (0.43) | MAPTHRH3HSD11B1CYP3A4ABL1 | |
| SCHEMBL20249226 | 0.86 | MAPT (0.45) | MAPTHRH3HSD11B1CYP3A4GPR119 | |
| SCHEMBL20255191 | 0.84 | HRH4 (0.43) | MAPTHRH3HSD11B1CYP3A4GPR119 | |
| SCHEMBL31615430 | 0.84 | CYP3A4 (0.55) | MAPTHRH3CYP3A4ABL1GPR119 | |
| SCHEMBL20249117 | 0.82 | HRH3 (0.49) | HRH3 | |
| SCHEMBL20224120 | 0.82 | CYP3A4 (0.47) | HRH3CYP3A4CDK1CDK2DHFR | |
| SCHEMBL20255106 | 0.82 | HRH4 (0.44) | HRH3CYP3A4 | |
| SCHEMBL22601459 | 0.82 | MAPT (0.50) | MAPTHRH3HSD11B1DHFR | |
| SCHEMBL20249100 | 0.81 | CDK4 (0.45) | MAPTHRH3CYP3A4GPR119CDK1 | |
| SCHEMBL21707135 | 0.81 | LCAT (0.37) | MAPTHRH3HSD11B1CYP3A4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | MAPT 2551/4885HRH3 2304/4885HSD11B1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.